• Passa al contenuto principale
BC

biochimica clinica

it_IT Italian
it_IT Italian en_US English
  • Home
  • Casi clinici
  • Ahead of print e Ultimo Fascicolo - Accedi per visualizzare gli articoli
  • Archivio BC fino a 2024
  • Sottometti un articolo
  • Norme Autori
  • Cerca

RASSEGNE - Reviews

Volume:

Biochimica Clinica 2019; 43(3) 264-268

Pubblicato on-line:

Luglio 4, 2019

DOI:

10.19186/BC_2019.050

Scarica in PDF:
Autenticazione richiesta

La diagnostica di laboratorio nella sindrome da apparente eccesso di mineralcorticoidi

AUTORI

Elisa Danese1, Davide Negrini1,2, Gian Luca Salvagno1, Chiara Zaltron3, Oliviero Olivieri3, Giuseppe Lippi1, Francesca Pizzolo3
1Sezione di Biochimica Clinica, Dipartimento di Neuroscienze, Biomedicina e Movimento, Università degli studi di Verona
2Dipartimento di Medicina di Laboratorio, Azienda Ospedaliera e Università di Padova
3Medicina Interna, Dipartimento di Medicina, Università degli studi di Verona

ABSTRACT

The laboratory diagnosis of apparent mineralocorticoid excess (AME)

The apparent mineralocorticoid excess(AME) is a rare genetic disorder caused by impaired activity of the enzyme 11β-hydroxysteroid dehydrogenase type2 (11βHSD2). This abnormality is associated with cortisol excess and abnormal activation of mineralocorticoidreceptor, which is usually only activated by aldosterone. More than 50 known mutations have been associated withAME; whilst some epigenetic modifications may also be involved. AME causes severe hypertension and is hencetraditionally diagnosed during the first years of life. Deficit of 11βHSD2 also occur in other physiopathologicalconditions like pre-eclampsia, sodium-sensitive hypertension and kidney or hepatic impairment. The biochemicaldiagnosis is conventionally made by quantifying tetrahydroxylated metabolites of cortisol (THF and allo-THF) andcortisone (THE) expressed as THF+allo-THF/THE ratio and using home-made Gas Chromatography-MassSpectrometry methods. Nevertheless, some recent studies showed more accurate characterization of 11βHSD2deficit by measuring the urinary free cortisol/cortisone ratio with Liquid Chromatography-Tandem Mass Spectrometry.A final consensus on the preferred method to diagnose AME has not been reached so far, and more studies areneeded for better defining sensitivity and specificity of these tests in some different physiopathological conditionsassociated with 11βHSD2 impairment.

BIBLIOGRAFIA

HOME
PRIVACY POLICY
5x1000 Docemus

LOGO SIBioC

EDITORE RESPONSABILE
Alberto Oliaro

EDITORIAL SECRETARY
Edizioni Minerva Medica S.p.A.
Corso Bramante 83-85, 10126 Torino
T +39 011 678282
journals.dept@minervamedica.it

Designed by Biomedia srl
© 2025 SIBioC
P. IVA IT 06484860967